FOLH1 and prostate cancer: Moreover, promising early clinical data has indicated that targeting PSMA with 225Ac via a small molecule (84, 94, 95) or an antibody (96) has substantial potential in advanced prostate cancer, including for patients who have received radiotherapeutics utilizing 177Lu (97), and suggests feasibility of using different targeted radionuclides sequentially.